Are we there yet? CAR-T therapy in multiple myeloma von Mirvis, Eitan, Benjamin, Reuben

Volltext

Allogeneic CAR-T Cells: More than Ease of Access? von Graham, Charlotte, Jozwik, Agnieszka, Pepper, Andrea, Benjamin, Reuben

Volltext

Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition von Condomines, Maud, Arnason, Jon, Benjamin, Reuben, Gunset, Gertrude, Plotkin, Jason, Sadelain, Michel

Volltext

LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma von Mateos, Maria-Victoria, Weisel, Katja, De Stefano, Valerio, Goldschmidt, Hartmut, Delforge, Michel, Mohty, Mohamad, Cavo, Michele, Vij, Ravi, Lindsey-Hill, Joanne, Dytfeld, Dominik, Angelucci, Emanuele, Perrot, Aurore, Benjamin, Reuben, van de Donk, Niels W. C. J., Ocio, Enrique M., Scheid, Christof, Gay, Francesca, Roeloffzen, Wilfried, Rodriguez-Otero, Paula, Broijl, Annemiek, Potamianou, Anna, Sakabedoyan, Caline, Semerjian, Maria, Keim, Sofia, Strulev, Vadim, Schecter, Jordan M., Vogel, Martin, Wapenaar, Robert, Nesheiwat, Tonia, San-Miguel, Jesus, Sonneveld, Pieter, Einsele, Hermann, Moreau, Philippe

Volltext

Poor outcome and prolonged persistence of SARS‐CoV‐2 RNA in COVID‐19 patients with haematological malignancies; King's College Hospital experience von Shah, Vallari, Ko Ko, Thinzar, Zuckerman, Mark, Vidler, Jennifer, Sharif, Sobia, Mehra, Varun, Gandhi, Shreyans, Kuhnl, Andrea, Yallop, Deborah, Avenoso, Daniele, Rice, Carmel, Sanderson, Robin, Sarma, Anita, Marsh, Judith, Lavallade, Hugues, Krishnamurthy, Pramila, Patten, Piers, Benjamin, Reuben, Potter, Victoria, Ceesay, M. Mansour, Mufti, Ghulam J., Norton, Sam, Pagliuca, Antonio, Galloway, James, Kulasekararaj, Austin G.

Volltext

Secondary HLH is uncommon in severe COVID‐19 von Wood, Henry, Jones, John R., Hui, Kit, Mare, Tracey, Pirani, Tasneem, Galloway, James, Metaxa, Victoria, Benjamin, Reuben, Rutherford, Andrew, Cain, Sharon, Kulasekararaj, Austin G.

Volltext

Gene-edited healthy donor CAR T cells show superior anti-tumour activity compared to CAR T cells derived from patients with lymphoma in an in vivo model of high-grade lymphoma von Graham, Charlotte Elizabeth, Jozwik, Agnieszka, Quartey-Papafio, Ruby, Ioannou, Nikolaos, Metelo, Ana M., Scala, Carlo, Dickson, Glenda, Stewart, Orla, Almena-Carrasco, Maria, Peranzoni, Elisa, Ramsay, Alan G., Patten, Piers E. M., Pertel, Thomas, Farzaneh, Farzin, Dupouy, Sandra, Pepper, Andrea, Benjamin, Reuben

Volltext

Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study von Camilleri, Marquita, Cuadrado, Maria, Phillips, Elizabeth, Wilson, William, Jenner, Richard, Pang, Gavin, Kamora, Sumaiya, Streetly, Matthew, Popat, Rakesh, Bygrave, Ceri, Owen, Roger, Cavenagh, James, Chapman, Mike, Sive, Jonathan, Eccersley, Lydia, Sheaff, Michael, Benjamin, Reuben, Ramasamy, Karthik, Cook, Gordon, Virchis, Andres, Chavda, Selina J., Clifton‐Hadley, Laura, Scully, Marie Anne, Yong, Kwee

Volltext

Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study von van de Donk, Niels W C J, Minnema, Monique C, van der Holt, Bronno, Schjesvold, Fredrik, Wu, Ka Lung, Broijl, Annemiek, Roeloffzen, Wilfried W H, Gadisseur, Alain, Pietrantuono, Giuseppe, Pour, Ludek, van der Velden, Vincent H J, Lund, Thomas, Offidani, Massimo, Grasso, Mariella, Giaccone, Luisa, Razawy, Wida, Tacchetti, Paola, Mancuso, Katia, Silkjaer, Trine, Caers, Jo, Zweegman, Sonja, Hájek, Roman, Benjamin, Reuben, Vangsted, Annette Juul, Boccadoro, Mario, Gay, Francesca, Sonneveld, Pieter, Musto, Pellegrino

Volltext

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk von Richard, Shambavi, Chari, Ajai, Delimpasi, Sosana, Simonova, Maryana, Spicka, Ivan, Pour, Ludek, Kriachok, Iryna, Dimopoulos, Meletios A., Pylypenko, Halyna, Auner, Holger W., Leleu, Xavier, Usenko, Ganna, Hajek, Roman, Benjamin, Reuben, Dolai, Tuphan Kanti, Sinha, Dinesh Kumar, Venner, Christopher P., Garg, Mamta, Stevens, Don Ambrose, Quach, Hang, Jagannath, Sundar, Moreau, Phillipe, Levy, Moshe, Badros, Ashraf, Anderson, Larry D., Bahlis, Nizar J., Facon, Thierry, Mateos, Maria Victoria, Cavo, Michele, Chang, Hua, Landesman, Yosef, Chai, Yi, Arazy, Melina, Shah, Jatin, Shacham, Sharon, Kauffman, Michael G., Grosicki, Sebastian, Richardson, Paul G.

Volltext

Engineering of an Avidity-Optimized CD19-Specific Parallel Chimeric Antigen Receptor That Delivers Dual CD28 and 4-1BB Co-Stimulation von Halim, Leena, Das, Kushal K, Larcombe-Young, Daniel, Ajina, Adam, Candelli, Andrea, Benjamin, Reuben, Dillon, Richard, Davies, David M, Maher, John

Volltext

Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma von Auner, Holger W., Gavriatopoulou, Maria, Delimpasi, Sosana, Simonova, Maryana, Spicka, Ivan, Pour, Ludek, Dimopoulos, Meletios A., Kriachok, Iryna, Pylypenko, Halyna, Leleu, Xavier, Doronin, Vadim, Usenko, Ganna, Hajek, Roman, Benjamin, Reuben, Dolai, Tuphan Kanti, Sinha, Dinesh Kumar, Venner, Christopher P., Garg, Mamta, Stevens, Don Ambrose, Quach, Hang, Jagannath, Sundar, Moreau, Phillipe, Levy, Moshe, Badros, Ashraf, Anderson, Larry D., Bahlis, Nizar J., Facon, Thierry, Mateos, Maria Victoria, Cavo, Michele, Chai, Yi, Arazy, Melina, Shah, Jatin, Shacham, Sharon, Kauffman, Michael G., Richardson, Paul G., Grosicki, Sebastian

Volltext

Efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice‐weekly bortezomib and dexamethasone in previously treated multip... von Delimpasi, Sosana, Mateos, Maria Victoria, Auner, Holger W., Gavriatopoulou, Maria, Dimopoulos, Meletios A., Quach, Hang, Pylypenko, Halyna, Hájek, Roman, Leleu, Xavier, Dolai, Tuphan Kanti, Sinha, Dinesh Kumar, Venner, Christopher P., Benjamin, Reuben, Garg, Mamta Krishnan, Doronin, Vadim, Levy, Yair, Moreau, Philippe, Chai, Yi, Arazy, Melina, Shah, Jatin, Shacham, Sharon, Kauffman, Michael G., Richardson, Paul G., Grosicki, Sebastian

Volltext

The combination of an inclusive novel agent treatment strategy, pre‐emptive therapy dose reduction, and prolonged therapy results in good outcomes in elderly myeloma patients von Ediriwickrama, Nadishani, Oyebamiji, Titi, Munisamy, Sreetharan, Garland, Paula, Cuthill, Kirsty, Benjamin, Reuben, Ceesay, M. Mansour, Bowcock, Stella

Volltext

Clinical proof of concept for a safe and effective NF‐κB‐targeting strategy in multiple myeloma von Tornatore, Laura, Capece, Daria, D'Andrea, Daniel, Begalli, Federica, Verzella, Daniela, Bennett, Jason, Acton, Gary, Campbell, Elizabeth A., Kelly, James, Tarbit, Michael, Adams, Nigel, Bannoo, Selina, Leonardi, Antonio, Sandomenico, Annamaria, Raimondo, Domenico, Ruvo, Menotti, Chambery, Angela, Oblak, Metod, Al‐Obaidi, Magda J., Kaczmarski, Richard S., Gabriel, Ian, Oakervee, Heather E., Kaiser, Martin F., Wechalekar, Ashutosh, Benjamin, Reuben, Apperley, Jane F., Auner, Holger W., Franzoso, Guido

Volltext

Language dysfunction-associated EEG findings in patients with CAR-T related neurotoxicity von Sokolov, Elisaveta, Karschnia, Philipp, Benjamin, Reuben, Hadden, Robert D M, Elwes, Robert C D, Drummond, Lee, Amin, Devyani, Paiva, Vitor, Pennisi, Alex, Herlopian, Aline, Frigault, Matthew, Sanderson, Robin, Inam, Shafqat, Cole, Andrew J, Dietrich, Jorg

Volltext

What are the difficulties in conducting randomised controlled trials of thromboprophylaxis in myeloma patients and how can we address these? Lessons from apixaban versus LMWH or as... von Sayar, Zara, Czuprynska, Julia, Patel, Jignesh P., Benjamin, Reuben, Roberts, Lara N., Patel, Raj K., Cornelius, Victoria, Arya, Roopen

Volltext

Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone von Sanchez, Larysa, Leleu, Xavier, Beaumont, Jennifer L., Yu, Hailin, Hudgens, Stacie, Simonova, Maryana, Auner, Holger W., Quach, Hang, Delimpasi, Sosana, Špička, Ivan, Pour, Ludĕk, Kriachok, Iryna, Dimopoulos, Meletios A., Usenko, Ganna, Hájek, Roman, Benjamin, Reuben, Sinha, Dinesh Kumar, Venner, Christopher, Illmer, Thomas, Garg, Mamta Krishnan, Stevens, Don Ambrose, Jagannath, Sundar, Levy, Moshe, Anderson, Larry D., Bahlis, Nizar Jacques, Facon, Thierry, Cavo, Michele, Chai, Yi, Ma, Xiwen, Tang, Shijie, Leong, Hoyee, Shah, Jatin, Shacham, Sharon, Kauffman, Michael, Richardson, Paul, Grosicki, Sebastian

Volltext

Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma von Mateos, Maria V, Gavriatopoulou, Maria, Facon, Thierry, Auner, Holger W, Leleu, Xavier, Hájek, Roman, Dimopoulos, Meletios A, Delimpasi, Sosana, Simonova, Maryana, Špička, Ivan, Pour, Ludĕk, Kriachok, Iryna, Pylypenko, Halyna, Doronin, Vadim, Usenko, Ganna, Benjamin, Reuben, Dolai, Tuphan K, Sinha, Dinesh K, Venner, Christopher P, Garg, Mamta, Stevens, Don A, Quach, Hang, Jagannath, Sundar, Moreau, Philippe, Levy, Moshe, Badros, Ashraf Z, Anderson, Jr, Larry D, Bahlis, Nizar J, Cavo, Michele, Chai, Yi, Jeha, Jacqueline, Arazy, Melina, Shah, Jatin, Shacham, Sharon, Kauffman, Michael G, Richardson, Paul G, Grosicki, Sebastian

Volltext

CAR T cells – the future for cancer therapy von Benjamin, Reuben

Volltext